JPS5848556B2 - Zinc compounds and their production method - Google Patents
Zinc compounds and their production methodInfo
- Publication number
- JPS5848556B2 JPS5848556B2 JP7540679A JP7540679A JPS5848556B2 JP S5848556 B2 JPS5848556 B2 JP S5848556B2 JP 7540679 A JP7540679 A JP 7540679A JP 7540679 A JP7540679 A JP 7540679A JP S5848556 B2 JPS5848556 B2 JP S5848556B2
- Authority
- JP
- Japan
- Prior art keywords
- zinc
- production method
- zinc compounds
- general formula
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Landscapes
- Thiazole And Isothizaole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
【発明の詳細な説明】
本発明は、一般式
は水素原
で表わされる新規な亜鉛化合物およびその製造法に関す
る。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a novel zinc compound whose general formula is represented by a hydrogen atom, and a method for producing the same.
上記式中、Ｒ１は低級アルキル基（メチル、エチル、プ
ロビル、インプロビルなど）を、Ｒ２は水素原子または
アルカリ金属原子（ナトリウム、カリウムなど）を示す
。In the above formula, R1 represents a lower alkyl group (methyl, ethyl, provil, improvil, etc.), and R2 represents a hydrogen atom or an alkali metal atom (sodium, potassium, etc.).
一般式（１）の亜鉛化合物は、一般式
〔式中、Ｒ１ およびＲ２は前記と同義であり、Ｍはア
ルカリ金属原子を示す。The zinc compound of general formula (1) has the general formula [wherein R1 and R2 have the same meanings as above, and M represents an alkali metal atom].
〕で表わされる化合物と、一般式
ＺｎＸ２
（ＩＩＩ）
〔式中、Ｘはハロゲン原子（ＣＩ、Ｂｒなと）、水酸基
もしくは低級脂肪酸エステル基
（ＣＨ３ＣＯＯ−，ＣＨ３ＣＨ２ＣＯＯ一など）または
Ｘ２はＣＯ３もしくはＳＯ４を示す。] and a compound represented by the general formula ZnX2 (III) [wherein, show.
〕で表わされる化合物、すなわち、・・ロゲン化亜鉛、
水酸化亜鉛、低級脂肪酸亜鉛、炭酸亜鉛または硫酸亜鉛
とを反応させることにより製造される。], i.e., zinc rogenide,
It is produced by reacting zinc hydroxide, lower fatty acid zinc, zinc carbonate or zinc sulfate.
この反応は通常、窒素、アルゴンなどの不活性ガス気流
中、水冷下、一般式（ＩＩ）で表わされるアルカリ金属
塩の水溶液中に、一般式（ＩＩＩ）で表わされる亜鉛化
合物の水溶液を加え、数分〜３０分間程度攪拌すること
により行われる。This reaction is usually carried out by adding an aqueous solution of a zinc compound represented by general formula (III) to an aqueous solution of an alkali metal salt represented by general formula (II) under water cooling in a stream of an inert gas such as nitrogen or argon, and This is carried out by stirring for several minutes to about 30 minutes.
目的物の単離・精製は常法により、この反応液にメタノ
ール、エタノール、アセトン、ジオキサンなどの親水性
有機溶媒を徐々に加えて目的物を析出させ、ついで必要
に応じて結晶化、洗浄、再結晶することにより行われる
。Isolation and purification of the target product is carried out by a conventional method. Hydrophilic organic solvents such as methanol, ethanol, acetone, and dioxane are gradually added to the reaction solution to precipitate the target product, followed by crystallization, washing, and treatment as necessary. This is done by recrystallization.
本発明の亜鉛化合物（Ｉ）は不斉炭素を有するが、本発
明は全ての立体異性体を包含するものである。Although the zinc compound (I) of the present invention has an asymmetric carbon, the present invention includes all stereoisomers.
本発明は、たとえば次の亜鉛化合物を提供するが、これ
らに限定されるものではない。The present invention provides, for example, the following zinc compounds, but is not limited thereto.
◎亜鉛一ビスＣ３−｛（２Ｓ）−３−メチルカブト−２
−メチルプロピオニル｝−４（Ｒ）チアゾリジカルボン
酸〕
◎亜鉛一ビスＣ ３−｛（２Ｓ）−３−メルヵプト−２
−メチルプロピオニル）−４（Ｒ）一チアゾリジンカル
ボン酸ナトリウム（またはカリウム）〕
本発明の亜鉛化合物（１）はアンジオテンシン１変換酵
素阻害作用を有し、味覚障害が改善されたものであり、
高血圧治療剤としてまたリウマチ治療剤としても有用で
ある。◎Zinc-bisC3-{(2S)-3-methylkabuto-2
-Methylpropionyl}-4(R)thiazolidicarboxylic acid] ◎Zinc-bisC 3-{(2S)-3-mercapto-2
-Methylpropionyl)-4(R)-monothiazolidinecarboxylic acid sodium (or potassium)] The zinc compound (1) of the present invention has angiotensin 1-converting enzyme inhibitory action and improves taste disorders,
It is also useful as a therapeutic agent for hypertension and rheumatism.
さらに亜鉛欠乏に伴う種々の症状の予防または治療に用
いられうる。Furthermore, it can be used to prevent or treat various symptoms associated with zinc deficiency.
本発明化合物を、高血圧治療薬として用いる場合、それ
自体または薬埋上許容されうる適宜の賦形剤、担体、希
釈剤などと混合し、錠剤、カブセル、顆粒、粉末または
注射剤などの形態で経口的または非経口的に投与するこ
とができる。When the compound of the present invention is used as a drug for treating hypertension, it may be prepared by itself or mixed with appropriate pharmaceutically acceptable excipients, carriers, diluents, etc., in the form of tablets, capsules, granules, powders, injections, etc. It can be administered orally or parenterally.
投与量は患者の症状、年齢、体重、薬物に対する反応に
より異なるが、通常成人１日当り、経口投与の場合、約
ＩＴｎ９から約１０００■の範囲で、１回または数回に
わけて投与される。The dosage varies depending on the patient's symptoms, age, weight, and response to the drug, but it is usually in the range of about ITn 9 to about 1000 μ per day for adults, once or in several doses.
また、他の循環器用薬剤、利尿剤などと併用して用いて
もよい。It may also be used in combination with other cardiovascular drugs, diuretics, etc.
次に実施例により本発明をより一層具体的に説明する。Next, the present invention will be explained in more detail with reference to Examples.
実施例
３−Ｃ（２Ｓ）−３−メルカプト−２−メチルプロピオ
ニル） −４ （ Ｒ ）一チアゾリジンカルボン酸９
．４１？を、窒素気流中、水酸化ナトリウム３．４１を
含む４０ＴＬｌの水溶液に溶解させ、これに塩化亜鉛２
．７２９を含む２０ｍｌの水溶液を水冷下に滴下する。Example 3-C(2S)-3-mercapto-2-methylpropionyl)-4 (R) monothiazolidinecarboxylic acid 9
．． 41? was dissolved in an aqueous solution of 40 TLl containing 3.41 parts of sodium hydroxide in a nitrogen stream, and 2 parts of zinc chloride was added to this solution.
．． 20 ml of an aqueous solution containing 729 is added dropwise while cooling with water.
ついで、反応液にアルコールを徐々に加えて白色粘稠性
物質を析出させる。Then, alcohol is gradually added to the reaction solution to precipitate a white viscous substance.
アルコールをデカントして除き、この粘稠性物質にアセ
トンを加えると、白色微結晶となる。The alcohol is decanted off and acetone is added to this viscous material, resulting in white microcrystals.
これを吸引沢取し、メタノールに溶解し、アセトンを徐
々に加えて結晶を析出させ、沢取し、乾燥する。This is collected by suction, dissolved in methanol, and acetone is gradually added to precipitate crystals, which is collected and dried.
かくして、融点２６４〜２６７℃（分解）の白色微結晶
として、亜鉛一ビス［ ３−｛ （ ２Ｂ ’） −３
−メルカプト−２−メチルプロピオニル｝−４（Ｒ）チ
アゾリジンカルボン酸ナトリウム〕が６，７ク得られる
。Thus, zinc bis[ 3-{ (2B')-3
-mercapto-2-methylpropionyl}-4(R) sodium thiazolidinecarboxylate] is obtained.
Claims (1)
カリ金属原子を示す。 〕で表わされる亜鉛化合物。[Claims] 1. General formula [wherein R1 represents a lower alkyl group, R2 represents a child or an alkali metal atom]. ] A zinc compound represented by
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7540679A JPS5848556B2 (en) | 1979-06-14 | 1979-06-14 | Zinc compounds and their production method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7540679A JPS5848556B2 (en) | 1979-06-14 | 1979-06-14 | Zinc compounds and their production method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS55167280A JPS55167280A (en) | 1980-12-26 |
| JPS5848556B2 true JPS5848556B2 (en) | 1983-10-28 |
Family
ID=13575257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7540679A Expired JPS5848556B2 (en) | 1979-06-14 | 1979-06-14 | Zinc compounds and their production method |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5848556B2 (en) |
-
1979
- 1979-06-14 JP JP7540679A patent/JPS5848556B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| JPS55167280A (en) | 1980-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6035350B2 (en) | dextrorotatory spirohydantoin | |
| US4299838A (en) | Tryptophan derivatives having an increased effect on the central nervous system | |
| SK18182002A3 (en) | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | |
| WO2020072964A1 (en) | Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors | |
| JPH0150700B2 (en) | ||
| JP2921124B2 (en) | Oxidized glutathione alkyl ester | |
| JP2000506876A (en) | 2- (3H) -oxazolone derivatives and their use as COX-2 inhibitors | |
| US3931212A (en) | Method for treating cardiovascular circulatory insufficiencies and hypotonia with 2-hydroxy-phenyl-1-oxa-4-azaspiroalkane derivatives | |
| SU1053749A3 (en) | Process for preparing (1,2-bis-nicotineamido)-propane or its salts with pharmaceutically acceptable acid | |
| JPS62270564A (en) | Pyrazine derivative and inhibitor of blood platelet aggregation containing same | |
| JPS5848556B2 (en) | Zinc compounds and their production method | |
| US2774787A (en) | Polyhydrophthalamic acid visceral smooth muscle relaxants | |
| JPH0573754B2 (en) | ||
| WO1980000444A1 (en) | Hydroxamic acid derivatives | |
| US3635971A (en) | 3 (3 4-dihydro-3-oxo-2-quinoxalinyl) propionamides | |
| US4464379A (en) | Indol acetic acid derivatives and anti-inflamatory and related uses thereof | |
| US5475028A (en) | 2-aminoethanesulfonic acid zinc complex | |
| US5489609A (en) | 2-aminoethanesulfonic acid zinc complex compound | |
| GB1565022A (en) | Methylamine derivatives and provesses for preparing the same | |
| JPS6317068B2 (en) | ||
| RU2067575C1 (en) | 4-acetyl-5-para-iodophenyl-1-carboxymethyl-3-hydroxy-2,5-dihyd- ropyrrol-2-one showing analgetic activity | |
| US3772378A (en) | 7-oxo-benzocycloheptene acetic acids | |
| US4548947A (en) | 1-(Substituted-aryl)-dihydro-1H-pyrrolizine-3,5-[2H,6H-]diones and use for reversing amnesia | |
| JPH01283263A (en) | Disubstituted pyrroles | |
| JPH0466568A (en) | Central antioxidant compound |